|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with banks | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Loans, net of allowance for loan losses of $1,522 and $1,523, respectively | ||||||||||||||||||||
| Loans, net of allowance for loan losses of $1,692 and $1,523, respectively | ||||||||||||||||||||
| Securities available for sale, at fair value | ||||||||||||||||||||
| Securities held to maturity | ||||||||||||||||||||
| Loans, net of allowance for credit losses of $2,329 and $1,692, respectively | ||||||||||||||||||||
| Federal Home Loan Bank stock, at cost | ||||||||||||||||||||
| Foreclosed real estate | ||||||||||||||||||||
| Premises and equipment | ||||||||||||||||||||
| Accrued interest receivable: | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Securities | ||||||||||||||||||||
| Cash value of life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Advances from Federal Home Loan Bank | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, 30,000,000 shares authorized, $0.01 par value, 3,565,430 shares issued and 2,885,039 shares outstanding (2,885,039 in 2022) | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings, substantially restricted | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Unearned ESOP shares | ||||||||||||||||||||
| Unearned stock compensation plan | ||||||||||||||||||||
| Treasury stock, at cost - 557,175 shares (548,777 in 2021) | ||||||||||||||||||||
| Treasury stock, at cost - 680,391 shares (680,391 in 2022) | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity |
Loading...
